DexCom (DXCM) closed at $86.04 on Oct 16, 2026, down 1.9% on the day. The stock is down 2.1% over the past month, up 13.7% over three months, up 29.6% year to date and up 31.5% over the past year. It trades 7.1% below its 52-week high of $92.59 and 59.0% above its 52-week low of $54.11. The close sits below its 50-day moving average ($87.55) and above its 200-day moving average ($73.97).
NextPick tracks DXCM in its Medical Devices basket alongside ABT, ISRG, MDT, SYK and BSX. As of Oct 16, 2026, the basket's money-flow score is 15 (weak inflow), and the basket is up 4.5% over five sessions. Over the past month DXCM ranks 13th of 13 basket members by price change.
DXCM is scheduled to report earnings on Oct 22, 2026.
DXCM options were pricing 49% at-the-money implied volatility on Oct 14, 2026, an IV rank of 37 over the past year.
DexCom is scheduled to report on Oct 22, 2026.
Yes — the Oct 16, 2026 close of $86.04 is 16.3% above the 200-day average of $73.97.
DXCM closed 7.1% below its 52-week high of $92.59.
NextPick groups DXCM with ABT, ISRG, MDT, SYK and BSX in its Medical Devices basket.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
